2 Information about anakinra

Marketing authorisation indication

2.1 Anakinra (Kineret, Sobi) is 'indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-Onset Still's Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids'. It can be given alone or with other anti-inflammatory drugs and disease‑modifying antirheumatic drugs.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The cost for 7 prefilled injections (each containing 100 mg anakinra per 0.67 ml) is £183.61 (excluding VAT; BNF online, accessed December 2020). The average cost of 1 year of treatment is £9,580.00.

  • National Institute for Health and Care Excellence (NICE)